3 results about "Pralatrexate" patented technology

The disclosure provides compositions and methods for treating peripheral T-cell lymphoma (PTCL) using a combination of Pralatrexate and COP.

SUMMARY This disclosure describes pralatrexate-containing compositions for subcutaneous administration. It also describes methods for administering these compositions, as described herein, for the treatment of diseases (e.g., lymphoma).

The invention relates to the technical field of biological medicine, in particular to application of a pralatrexate derivative as a UGT1A6 inhibitor. Computer simulation finds that the pralatrexate derivative can be stably combined to an N-terminal structural domain of UGT1A6, so that the normal physiological function of UGT1A6 protein is inhibited, and the pralatrexate derivative can be used as a UGT1A6 inhibitor. Besides, in-vitro experiments prove that the pralatrexate derivative can remarkably inhibit interaction between UGT1A6 and binding protein thereof, reduce the activity of gastric cancer cells and inhibit proliferation, migration and infiltration of the gastric cancer cells in a gastric cancer cell line, so that the pralatrexate derivative can be used for preparing drugs for treating or improving gastric cancer and gastric cancer tumor metastasis.